Combivent Respimat vs. Spiriva Respimat

Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray and Spiriva Respimat (tiotropium bromide) Inhalation Spray contain bronchodilators and are used to treat chronic obstructive pulmonary disease (COPD).

Side effects of Combivent Respimat and Spiriva Respimat that are similar include cold symptoms (stuffy nose, sneezing, cough, or sore throat), urinary retention, and fast heartbeat.

Side effects of Combivent Respimat that are different from Spiriva Respimat include headache, flu-like symptoms, nausea, vomiting, nervousness, difficulty breathing, and irregular heartbeat.

Side effects of Spiriva Respimat that are different from Combivent Respimat include dry mouth, sinus infection (sinusitis), constipation, difficulty urinating, urinary tract infection (UTI), upper respiratory tract infection, non-specific chest pain, indigestion, blurred vision, dizziness, oral thrush, diarrhea, fever, and high blood pressure.

Both Combivent Respimat and Spiriva Respimat may interact with other anticholinergic medications.

Combivent Respimat may also interact with other bronchodilators, bladder or urinary medicines, diuretics (water pills), heart or blood pressure medications, medications for Parkinson's disease or depression, stimulants, ADHD medications, diet pills, over-the-counter cold or allergy medicine, and medications to treat excess stomach acid, stomach ulcers, motion sickness, or irritable bowel syndrome.

Common side effects of Combivent Respimat include:

• headache,
• cold symptoms (stuffy nose, sneezing, cough, or sore throat),
• flu-like symptoms,
• nausea,
• vomiting,
• nervousness,
• difficulty breathing,
• urinary retention and
• fast or irregular heartbeat.

Serious side effects of Combivent Respimat include:

• bronchospasms,
• eye (ocular) changes, and
• heart (cardiac) complications.

Common side effects of Spiriva Respimat include:

• sore throat,
• cough,
• dry mouth,
• sinus infection (sinusitis),
• constipation,
• difficulty urinating,
• urinary retention,
• urinary tract infection (UTI),
• upper respiratory tract infection,
• non-specific chest pain,
• indigestion,
• runny nose,
• increased heart rate,
• blurred vision,
• dizziness,
• oral thrush,
• diarrhea,
• fever, and
• high blood pressure.

Combivent Respimat (sunitinib malate) is a multi-kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor after disease progression on, or intolerance to imatinib mesylate, for advanced renal cell carcinoma, and for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease. Combivent Respimat is available in generic form.

Spiriva Respimat (tiotropium bromide) Inhalation Spray is an anticholinergic drug used for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Spiriva Respimat is indicated to reduce exacerbations in COPD patients.

Combivent Respimat may interact with bladder or urinary medicines, diuretics (water pills), heart or blood pressure medications, medications for Parkinson's disease or depression, other bronchodilators, stimulants, ADHD medications, diet pills, over-the-counter cold or allergy medicine, or medication to treat excess stomach acid, stomach ulcer, motion sickness, or irritable bowel syndrome. Tell your doctor all medications and supplements you use.

Spiriva Respimat may interact with other anticholinergic medications. Tell your doctor all medications and supplements you use.

The Combivent Respimat inhaler delivers 20 mcg of ipratropium bromide (monohydrate) and 100 mcg albuterol (equivalent to 120 mcg albuterol sulfate) from the mouthpiece. The recommended dose of Combivent Respimat is one inhalation four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed six within 24 hours.

The recommended dose of Spiriva Respimat is two inhalations once-daily. Do not take more than one dose (2 inhalations) in 24 hours.